Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.
IDEV vs XBI: how they differ
IDEV and XBI hold 0% of their weight in the same names, and XBI returned more over the year.
iShares Core MSCI International Developed Markets ETF and State Street(R) SPDR(R) S&P(R) Biotech ETF.
What they hold in common
By the books each fund has filed, IDEV and XBI hold 0% of their money in the same securities at the same weight.
| Only in IDEV | Only in XBI |
|---|---|
| ASML Holding N.V. 1.95% | Apogee Therapeutics Inc 1.49% |
| HSBC HOLDINGS PLC 1.09% | Moderna Inc 1.41% |
| ASTRAZENECA PLC 1.02% | Twist Bioscience Corp 1.41% |
| Novartis AG 0.97% | Oruka Therapeutics Inc 1.38% |
| SHELL PLC 0.90% | Kymera Therapeutics Inc 1.36% |
| Nestle S.A. 0.90% | Viking Therapeutics Inc 1.31% |
| ROYAL BANK OF CANADA 0.87% | Praxis Precision Medicines Inc 1.29% |
| Siemens Aktiengesellschaft 0.78% | Erasca Inc 1.27% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Apr 30, 2026 and Jun 30, 2026.
| IDEV iShares Core MSCI International Developed Markets ETF | XBI State Street(R) SPDR(R) S&P(R) Biotech ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | iShares | State Street |
| What it is | Core MSCI International Developed Markets | SPDR S&P Biotech |
| Total return, 1 year | +18.7% | +64.0% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | +1.2 pts | +46.5 pts |
| Expense ratio | 0.04% | 0.35% |
| Already in the S&P 500 | 0.1% | 8.5% |
| Holdings | 2268 | 150 |
IDEV in plain words
IDEV is an index equity fund tracking the Core MSCI International Developed Markets. Over the year to Sep 11, 2026 it returned +18.7% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.04% a year. By its holdings filed for Apr 30, 2026, 0% of the fund by weight is stocks the S&P 500 also holds, across 2268 positions, with the top ten at 10.2%.
XBI in plain words
XBI is an index equity fund tracking the SPDR S&P Biotech. Over the year to Sep 11, 2026 it returned +64.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.35% a year. By its holdings filed for Jun 30, 2026, 8% of the fund by weight is stocks the S&P 500 also holds, across 150 positions, with the top ten at 13.3%. It sat 9.6% below its high of Feb 8, 2021 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, IDEV or XBI?
- In the year to Sep 12, 2026, with distributions reinvested, IDEV returned +18.7% and XBI returned +64.0%, so XBI returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, IDEV or XBI?
- IDEV charges 0.04% a year and XBI charges 0.35%, so IDEV is cheaper. Fees come from each fund's prospectus.
- How much do IDEV and XBI overlap with the S&P 500?
- By their latest filed holdings, 0% of IDEV and 8% of XBI by weight is stocks the S&P 500 already holds. Between the two funds, 0% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, IDEV against XBI, data as of Sep 12, 2026. https://etfiq.com/compare/any/IDEV-XBI Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources